Monod Bio and SignalChem Biotech, a wholly owned subsidiary of Sino Biological, announced a non-exclusive licensing agreement covering Monod Bio’s LuxSit de novo luciferase technology and NovoBodies. SignalChem plans to incorporate the AI-designed protein technologies into custom luminescent assay development and protein-fusion services. The deal signals continued industrialization of AI-designed proteins for applied assay workflows, not just discovery. For SignalChem, it expands service offerings and customer reach; for Monod Bio, it extends commercial distribution via Sino’s global tools footprint. Both companies positioned the collaboration around speeding discovery candidates through more efficient assay development, which could tighten timelines for biopharma and research customers using luminescence-based readouts.